

RHINOMED


MAY 2017 INVESTOR UPDATE

This document contains certain forward-looking statements, relating to Rhinomed Limited's (Rhinomed) business which can be identified by the use of forward looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of the company's technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any specific health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, technology, financial result, and business prospects. Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

**RHINOMED IS A RESPIRATORY AND NASAL
MEDICAL TECHNOLOGY FIRM WITH AN
EXTENSIVE INTELLECTUAL PROPERTY
PORTFOLIO THAT FOCUSES ON THE ROLE
AND FUNCTION OF THE NOSE**


A NOVEL NASAL TECHNOLOGY PLATFORM

Our technology platform is protected by a family of over 60 patents, 57 design patents, brands and trademarks.



GROWING REVENUE FROM IN MARKET PRODUCTS

- Two applications already brought to market- both of which are nasal stents.
- One in four people will have a problem breathing through their nose.
- Turbine and Mute help people to breathe better, sleep better and enjoy a better quality of life.



- TURBINE
- Helps athletes to breathe easier during sport and aerobic exercise and overcome nasal obstruction
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US\$24.95 delivering strong margins




- Mute
- Helps breathing at night, improves nasal airflow and may alleviate snoring
- Adjustable for each nostril to ensure comfort and fit
- Available in a trial pack (contains 3 different sizes) and three sizes (small, medium & large)
- RRP US\$24.95 delivering strong margins

MUTE AND TURBINE - BREAK THROUGH RESPIRATORY TECHNOLOGY

MUTE AND TURBINE

- are fully adjustable
- harness 'Poiseuille's law'- if the diameter of the nose increases by 1, the volume of the airway will increase by the power of 4
- Outperforms the external nasal strip market leader - delivering an average of 38% more air



Proprietary ratchet mechanism that delivers perfect individualised fit, gently expands the nostril delivering airflow to the power of 4



Dilates from the back of the nose minimising pressure on the Septum


Designed to mold to the internal surface of the nostril

MUTE TARGETS ONE OF THE **FASTEST GROWING MARKETS IN HEALTH - SLEEP**

- Sleep Aids Market estimated to be US\$ 7 Billion in 2015
- Forecast to grow to US\$ 10 billion by 2020 at a CAGR of 6.4% from 2016 to 2020.





Apple included a new 'blue light' function in their new iPhone OS release in March '16



Huffington Post founder Arianna Huffington is taking the US by storm



Sleep is being picked up by mainstream media as a 'health story'




THE SLEEP CATEGORY REPRESENTS **A MAJOR COMMERCIAL OPPORTUNITY**

Snorers can't find an effective OTC solution:

- 73% of nasal spray users find them ineffective
- 81% of throat spray users find them ineffective
- 75% of nasal strip users find them ineffective
- there has been a lack of medically backed innovation
- value for money has been poor

CONSUMERS RATE POPULAR SNORING SOLUTIONS

n=867



YouGov, 2015

A CLEAR PROPOSITION TO CONSUMER AND CLINICAL MARKETS

BETTER SLEEP
STARTS WITH BETTER
BREATHING

1 IN 4


PEOPLE HAVE TROUBLE
BREATHING THROUGH
THEIR NOSE



BETTER BREATHING
STARTS WITH THE NOSE

MUTE TARGETS NASAL
OBSTRUCTION

INCREASES AIRFLOW BY 38%*



Condition	Airflow (CC/SECOND)
BASELINE	450
RHINOMED TECHNOLOGY	618

*S.BRAHAM, ROYAL VICTORIAN EYE AND EAR HOSPITAL 2003

BETTER SLEEP
STARTS WITH
THE NOSE

MUTE STENTS THE NASAL
AIRWAY

TARGETS NASAL
OBSTRUCTION &
CONGESTION



BREATHE MORE,
SNORE LESS,
SLEEP BETTER.



RHINOMED
mu:te
BREATHE MORE
SNORE LESS

MEDIUM
3 PACK (30 NIGHT SUPPLY)

NASAL DEVICE

BUILDING OUT A MULTI LEVEL DISTRIBUTION CHANNEL



SPECIALTY RETAIL



MAINSTREAM RETAIL



ONLINE



PHARMACY & GROCERY



CLINICAL

RHINOMED TECHNOLOGY NOW AVAILABLE IN LEADING GLOBAL RETAIL OUTLETS

Since February 2014 opened up over 7000 retail outlets:




Since February 2014 established key global wholesale relationships:



GROWING LEVEL OF SUPPORT FROM CUSTOMERS AND CLINICIANS



Growing adoption in sport and exercise market:
3 x Tour de France, Gold and Bronze Olympic medals



Huge consumer and media response to innovation in the sleep category. Growing number of advocates and ambassadors:



Growing acceptance from leading sleep specialists, dentists and ENT's



ESTABLISHED GLOBAL PRODUCTION AND LOGISTICS NETWORK



- Provides global logistics support from its Hong Kong hub
- Fulfillment to key US and European Distribution warehouses
- Provides direct to consumer fulfillment services




- Situated in Jiaotang, Gaoyao, Zhaoqing in Guangdong
- Certified ISO13485-2003 and QSR820 facility
- RNO has 5 dedicated tooling, production, assembly and packaging lines - production capacity of 3 million pack pa.



- Provides UK warehousing, customs and logistics support
- Distribution into Boots warehouses
- Provides direct to consumer fulfillment services for UK, IE and EU.

STRONG STORE NUMBER GROWTH IN KEY MARKETS

8000 STORE FOOTPRINT GROWTH




- Growing footprint in Australia, UK, Canada and USA
- Primarily retail pharmacy
- Strong pipeline of additional 20,000 stores
- Maintaining high gross margins during sell in process

DELIVERING REVENUE GROWTH


Steady growth in units shipped to customers:

- Up 25% in Q3
- Total units shipped FY17 YTD - 116,000

REVENUE FROM OPERATIONS



ENTERING THE US\$8 BILLION DECONGESTION MARKET



MUTE

- In market
- Resolves snoring
- Improves sleep quality
- Adjunct to existing sleep therapies



COUGH-COLD/
ALLERGY/
SINUS
\$8.7/20.3%

MUTE 'CLEAR'

- Next generation multi formulation platform
- Overnight nasal decongestant
- Class 1 product - regulatory process commencing
- Design being finalised and production scoping underway

VITAMINS AND SUPPLEMENTS¹
\$6.7/15.7%

GLOBAL SLEEP APNEA MARKET REPRESENTS A SIGNIFICANT OPPORTUNITY

Lack of Early Diagnosis

- 80% of people with sleep apnea remain undiagnosed
- Lack of awareness and fear of existing therapies driving low diagnosis rates globally

Poor compliance with existing therapies

- CPAP compliance and adherence rates are as low as 43%

Therapy cost/Value equation

- CPAP and MAD treatment is expensive - \$2000+
- Pressure from 'payers' to prove value equation
- Strong demand for innovation from patients, clinicians and insurers



DISRUPTING THE US\$ 32 BILLION GLOBAL SLEEP APNEA MARKET

INTRA NASAL POSITIVE EXPIRATORY AIRWAY PRESSURE (INPEAP) TECHNOLOGY

- Patented technology
- Targeting the 70% of OSA patients with Mild to moderate OSA - (AHI 14-29)
- Internal nasal delivery of Positive Expiratory Airway Pressure that will keep airway open during sleep
- Low invasive solution when compared to CPAP and Oral devices
- Successfully completed Phase 1 trial showing
 - nasally delivered EPAP
 - Well tolerated - 78% compliance



Rhinomed INPEAP prototype 1.0

DELIVERING END TO END SLEEP CATEGORY SOLUTIONS

SNORING

**NASAL
CONGESTION**

**MILD/
MODERATE
SLEEP APNEA**

**SEVERE SLEEP
APNEA**



MUTE CLEAR

Aroma enhanced
(menthol, eucalypt,
sleep & relaxation
blends)

RNO INPEAP

Phase IIb
being scoped

COMPANION THERAPY

MUTE + CPAP Mask
MUTE/INPEAP +
Mandibular Splint

GROWTH DRIVERS

RETAIL



- Scale in store numbers in Australia, USA, Canada and UK – Target: 13,000 FY17
- Premium in-store experience and presence – Drive sell-through
- Establish Mute technology as the entry point to the global sleep category

ONLINE



- Leading provider of content that informs and educates
- Curate an active and vibrant community and conversation

CLINICAL



- Become the preferred solution for nasal obstruction by Doctors and Dentists

CORPORATE SUMMARY

GLOBALLY EXPERIENCED BOARD OF DIRECTORS

Mr Ron Dewhurst - Chairman

Previously Head of Americas JP Morgan, EVP Head of Global Investment Managers Legg Mason Inc, MD of IOOF Holdings Ltd, CEO ANZ McCaughan Ltd. Currently Director of OneVue Ltd

Mr Michael Johnson - CEO and Managing Director

CEO and MD since February 2013, Director Cogentum Advisory, Previously Director Cetus Energy, Principal Strategyn

Mr Brent Scrimshaw - Non Exec Director

Previously VP & CEO Nike Western Europe, VP & CMO Nike Europe, Middle East & Africa, GM Nike USA (East), CMO Nike Australia and NZ. Currently Non Exec Director Catapult Ltd (ASX: CAT) and CEO Unscript'd Pty Ltd

Dr Eric Knight - Non Exec Director

Previously Lawyer Baker McKenzie, Consultant Boston Consulting Group. Currently Pro-Vice Chancellor University of Sydney, member Commonwealth Administrative Appeals Tribunal

ASX: RNO

FY17 Financial Position (as at Q3)

Cash - \$2.9 Million
Revenues FY17 YTD \$1.4m
Receipts FY17 YTD \$1.7m
Units shipped FY17 YTD - 116,000
Strong Gross Margins
Net Burn for Q3 - 79k

Top 20 - 47%

Capital Structure

Market Cap - \$19m

Shares on issues - \$93m

Offices

Melbourne, Australia
Cincinnati, USA

INVESTMENT PROPOSITION




MARKET

Compelling technology in a growing global market - Sleep



DISTRIBUTION

Business is rapidly expanding the revenue base through a global distribution footprint



KEY FOCUS

- USA & CANADA
- UK
- Aust/NZ Base



NEAR-TERM NEWS FLOW

- Growing number of distributors



COMPELLING INVESTMENT COMPARATOR

- Breathe Right Strips - Peak revenues of approximately US\$150m
- Purchased by GSK - US\$566m in 2007

MICHAEL JOHNSON, CEO
e. mjohnson@rhinomed.global
t. +61 3 8416 0900
www.rhinomed.global

© RHINOMED LTD.